Nutriband Inc.
NTRB
$5.73
-$0.10-1.72%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
4/30/2025
-
MarketBeat
4/30/2025
-
The Fly
4/30/2025
-
The Fly
4/30/2025
-
GuruFocus
4/30/2025
-
GuruFocus
4/30/2025
-
GuruFocus
4/30/2025
-
The Fly
4/30/2025
-
Globe Newswire
4/23/2025
-
MarketBeat
4/11/2025
-
GuruFocus
4/11/2025
-
GuruFocus
4/11/2025
-
GuruFocus
4/11/2025
-
TipRanks Financial Blog
4/11/2025
-
The Fly
4/11/2025
-
Globe Newswire
4/4/2025
-
GuruFocus
4/4/2025
-
GuruFocus
4/4/2025
-
Globe Newswire
4/4/2025
-
GuruFocus
4/4/2025
-
SeekingAlpha.com: All News
4/4/2025
-
GuruFocus
4/4/2025
-
TipRanks Financial Blog
4/4/2025
-
The Fly
4/4/2025
-
Globe Newswire
4/2/2025
-
Ticker Report
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, April 28, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 26 and 30 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
407 377 6695
Address
121 South Orange Avenue
Orlando, FL 32801
Orlando, FL 32801
Country
Year Founded
Business Description
Sector
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that...
more